{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:43:21Z","timestamp":1772613801224,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015639","name":"Japan Cardiovascular Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015639","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ijcard.2018.04.131","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T19:58:37Z","timestamp":1525291117000},"page":"108-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study"],"prefix":"10.1016","volume":"265","author":[{"given":"Satoshi","family":"Yasuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kaikita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Akao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Ako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2018.04.131_bb0005","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1161\/STROKEAHA.107.504993","article-title":"Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study","volume":"39","author":"Toyoda","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2018.04.131_bb0010","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jjcc.2009.12.014","article-title":"Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents","volume":"55","author":"Uchida","year":"2010","journal-title":"J. Cardiol."},{"issue":"2016","key":"10.1016\/j.ijcard.2018.04.131_bb0015","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"issue":"2011","key":"10.1016\/j.ijcard.2018.04.131_bb0020","volume":"57","author":"Fuster","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0025","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1161\/CIRCULATIONAHA.117.029994","article-title":"Impact of coronary computed tomography angiography findings on initiation of cardioprotective medications","volume":"136","author":"Chang","year":"2017","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0030","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0035","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0040","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0045","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0050","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"Heidbuchel","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2018.04.131_bb0055","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0060","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/eurheartj\/eht428","article-title":"Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial","volume":"35","author":"Mahaffey","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001592","article-title":"Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials","author":"Mak","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijcard.2018.04.131_bb0075","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1253\/circj.CJ-66-0092","article-title":"Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): digest version","volume":"78","author":"Japanese Circulation Society Joint Working Group","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0080","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of atrial fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2018.04.131_bb0085","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1253\/circj.CJ-88-0001","article-title":"Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): Digest version","volume":"74","author":"Japanese Circulation Society Joint Working Group","year":"2010","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2011.11.024","article-title":"Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study","volume":"125","author":"Olesen","year":"2012","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2133\/dmpk.DMPK-12-RG-034","article-title":"Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation","volume":"28","author":"Tanigawa","year":"2013","journal-title":"Drug. Metab. Pharmacokinet."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2133\/dmpk.DMPK-12-RG-109","article-title":"Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients","volume":"28","author":"Kaneko","year":"2013","journal-title":"Drug. Metab. Pharmacokinet."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0105","author":"Bayer Yakuhin, Ltd"},{"key":"10.1016\/j.ijcard.2018.04.131_bb0110","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1253\/circj.CJ-14-0266","article-title":"Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention","volume":"78","author":"Isshiki","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0115","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0120","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.04.131_bb0130","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317367554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317367554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:39:33Z","timestamp":1759091973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527317367554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":25,"alternative-id":["S0167527317367554"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.04.131","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.04.131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}